
Gene knockout cell lines are generated using CRISPR-Cas9 based technology to precisely disrupt target genes, enabling functional genomics research, disease modeling, and target validation.
ZNF286A (zinc finger protein 286A) encodes a predicted zinc finger transcription factor involved in RNA polymerase II-dependent transcriptional regulation. The protein is predicted to bind specific cis-regulatory DNA sequences and regulate gene expression. It is predicted to function in the nucleus, consistent with a potential role in transcriptional control.
The SU-DHL-1 cell line was established in 1973 from the pleural effusion of a 10-year-old male patient. Originally diagnosed as diffuse histiocytic lymphoma, the tumor was subsequently reclassified as diffuse large cell lymphoma and later as malignant histiocytosis. According to the REAL/WHO classification, the cell line represents anaplastic large cell lymphoma (ALCL) and carries the t(2;5)(p23;q35) translocation resulting in an NPM1-ALK (NPM-ALK) fusion gene. SU-DHL-1 is used as a model for studying ALCL biology and ALK-associated oncogenic signaling.
Comprehensive quality control includes STR authentication, sterility testing (bacteria and fungi), and mycoplasma screening to ensure purity and performance. Genotype is confirmed by two rounds of PCR and Sanger sequencing, and complete validation reports are provided for make-to-order products.

Cas9 cell lines in our cell bank can stably express Cas9 protein. Each Cas9 Stable Cell Line is easy to use and enables gene knockout simply by transfecting gRNA, while transfection of gRNA and donor DNA results in gene knock-in or point mutations
These Cas9 stable cell lines have been used to construct the KO cell lines for various genes, gene KO efficiency 5-10 times improved.
Selected cells, low passages, good cell condition, high activity, applicable for all kinds of gene-editing experiments.

Targeted knockout region: EExon 3
Reference Transcript: NM_001288643
Frameshift Mutation Strategy
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use





Simply fill out the form below to leave your inquiry
— we will respond within 24 Hours.
* Name
* Institution
* Products & Services of Interest
If email is not available, how else can we reach you?
How did you hear about us?